发明授权
- 专利标题： Synergistic anti-CD47 therapy for hematologic cancers
- 专利标题（中）： 协同抗CD47治疗血液癌
-
申请号： US13394060申请日： 2010-09-15
-
公开(公告)号： US08758750B2公开(公告)日： 2014-06-24
- 发明人: Irving L. Weissman , Ravindra Majeti , Arash Ash Alizadeh , Mark P. Chao
- 申请人： Irving L. Weissman , Ravindra Majeti , Arash Ash Alizadeh , Mark P. Chao
- 申请人地址： US CA Palo Alto
- 专利权人： The Board of Trustees of the Leland Stanford Junior University
- 当前专利权人： The Board of Trustees of the Leland Stanford Junior University
- 当前专利权人地址： US CA Palo Alto
- 代理机构： Bozicevic, Field & Francis LLP
- 代理商 Pamela J. Sherwood; Kyle A. Gurley
- 国际申请： PCT/US2010/048992 WO 20100915
- 国际公布： WO2011/034969 WO 20110324
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; A61K39/00
摘要：
Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.
公开/授权文献
- US20120282174A1 Synergistic Anti-CD47 Therapy for Hematologic Cancers 公开/授权日：2012-11-08
信息查询
